icodextrin and Diabetes-Mellitus

The use of icodextrin as an osmotic agent in solutions for peritoneal dialysis (PD) has important cardiovascular effects related with better control of extracellular volume. Among them, reduction of arterial pressure and an improvement in echocardiographic parameters stand out. In diabetic patients, icodextrin has additional potential advantages related with better metabolic control. In a multicenter, open-label randomized controlled trial, the effects of icodextrin solutions were compared to glucose solutions on echocardiographic, electrocardiographic, and blood pressure changes in diabetic patients on PD. Two phases were noted in the follow-up. In the early phase (6 months), reduction in ambulatory blood pressure (ABP) and left ventricular end diastolic diameter were found in the icodextrin group. These changes correlated with changes in body fluids. In the late phase (12 months), a trend towards baseline values in ABP was seen. Changes in inferior vena cava diameter and in low frequency R-R variability spectral analysis in the icodextrin group suggest that icodextrin increases circulating blood volume and sympathetic tone, probably by accumulation of icodextrin metabolites in the bloodstream and improvement in diabetic neuropathy as a result of lower peritoneal glucose absorption. The effects of icodextrin in diabetic patients were related to better fluid management and metabolic control.

Topics: Aged; Blood Pressure; Blood Volume; Diabetes Complications; Diabetes Mellitus; Dialysis Solutions; Electrocardiography; Female; Glucans; Glucose; Heart Rate; Heart Ventricles; Humans; Icodextrin; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Ultrasonography; Water-Electrolyte Balance

Icodextrin could reduce the risk of technique failure and improve patient survival in peritoneal dialysis (PD) patients. This study compared the survival between incident hemodialysis (HD) and PD patients, with and without diabetes, in the era of icodextrin treatment.. From the Taiwan health insurance database, 53,103 incident end-stage renal disease patients undergoing dialysis were identified from 2005 to 2010. The mortality risks among HD and PD patients with or without icodextrin treatment were compared. The follow-up period started from the date of dialysis initiation to December 31, 2011. The competing-risks regression model was used to estimate the subhazard ratio (SHR) of death with considering renal transplantation as a competing event.. Compared with the corresponding HD patients, mortality risks were higher in diabetic PD patients with icodextrin treatment (Bonferroni adjusted SHR=1.16, 98.3% CI=1.04-1.30) and without the treatment (Bonferroni adjusted SHR=1.35, 98.3% CI=1.16-1.57), particularly for elderly patients. Mortality risks for patients without diabetes were not different among the three cohorts. The time-dependent competing-risks model showed that PD patients with icodextrin treatment exhibited a reduced risk of death for diabetic patients, compared with those without icodextrin treatment (adjusted SHR=0.84, 95% CI=0.72-0.97).. Icodextrin could attenuate the survival disadvantage for PD relative to HD in diabetic patients, particularly for the elderly patients.

Topics: Aged; Comorbidity; Databases, Factual; Diabetes Mellitus; Female; Glucans; Glucose; Humans; Icodextrin; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Renal Dialysis; Retrospective Studies; Risk Factors; Survival Analysis; Taiwan; Time Factors; Treatment Outcome

Icodextrin can enhance ultrafiltration and consequently improve fluid balance and can control blood pressure and reduce left ventricular mass for peritoneal dialysis (PD) patients. This study investigated whether icodextrin use could reduce the risk of congestive heart failure (CHF) for PD patients.. From the Taiwan National Health Insurance database, we identified 5462 newly diagnosed end-stage renal disease patients undergoing PD from 2005 to 2010. Incidence rates and hazard ratio of CHF were estimated for patients with and without icodextrin treatment by the end of 2011.. Among PD patients, icodextrin users had an overall 26% lower incidence of CHF than non-users (13.7 vs 18.6 per 1000 person-years). Relatively, the adjusted hazard ratio was 0.67 (95% CI = 0.52-0.87) for users compared with non-users. Among PD patients with diabetes, the incident CHF in icodextrin users was 37.5% lower than that in non-users (17.8 vs 28.5 per 1000 person-years). Among PD patients without diabetes, the incident CHF in icodextrin users was 30.4% lower than that in non-users (11.0 vs 15.8 per 1000 person-years).. Icodextrin solution could reduce the risk of new-onset CHF, particularly effective when diabetic PD patients use it.

Topics: Aged; Blood Pressure; Comorbidity; Diabetes Mellitus; Dialysis Solutions; Female; Heart Failure; Heart Ventricles; Humans; Icodextrin; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Proportional Hazards Models; Taiwan; Water-Electrolyte Balance

Topics: Adult; Blood Glucose; Computers, Handheld; Coronary Artery Disease; Diabetes Mellitus; Diagnostic Errors; Dialysis Solutions; Glucans; Glucose; Humans; Hypoglycemia; Icodextrin; Kidney Failure, Chronic; Male; Peritoneal Dialysis; Reproducibility of Results

By 31 December 2006, more than 260,000 patients were on dialysis therapy in Japan, and 9,243 of them (3.6%) were on peritoneal dialysis (PD). The mean age of PD patients was 5 years less than that of all patients with chronic kidney disease, and the prevalence of diabetes among them was 9.4% lower. Among the PD patients, 18.0% were being treated with a combination of PD and hemodialysis, and 33.4% were being treated with automated PD. A peritoneal equilibration test (PET) had been performed in 22.0% of the patients, who were then classified into the four PET categories. Of the tested patients, 10.3% were placed in the low (L) category; 38.3% in the low-average (LA) category; 38.4%, in the high-average (HA) category; and 13.0%, in the high (H) category. Icodextrin was used by 27.3% of patients classified L, 30.5% of those classified LA, 47.1% of those classified HA, and 55.1% of those classified H. The annual death rate was 6.1%, which was lower than the rate for HD (9.7%); and the annual withdrawal rate was 19.8%. Infectious complications were the main cause for lowered rates of patient and technique survival. Use of PD for older and diabetic patients and of combination therapy with hemodialysis are key perspectives in the most recent report on PD in Japan.

Topics: Age Factors; Comorbidity; Diabetes Mellitus; Dialysis Solutions; Drug Utilization; Female; Glucans; Glucose; Humans; Icodextrin; Japan; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Surveys and Questionnaires; Survival Rate

A preliminary report from our unit previously suggested that diabetic patients on continuous cyclic peritoneal dialysis (CCPD) have higher ultrafiltration (UF) with icodextrin than non-diabetic patients. To confirm this observation, we did a retrospective analysis of our patients (17 diabetic and 23 non-diabetic) who were on stable CCPD prescription using a long-day dwell with icodextrin. We collected daily UF data from these patients' records for 30 days. The two groups showed no significant difference with respect to age, gender, hemoglobin, serum albumin, peritoneal dialysis and icodextrin vintage, peritoneal membrane characteristics, CCPD prescription, and peritoneal and residual renal clearance. The overnight net UF achieved with the cycler with standard glucose dialysate was similar in the two groups (850+/-379 in diabetic vs 713+/-484 ml/day in non-diabetic, P=0.34). However, UF with icodextrin during the day dwell (14.8+/-0.8 h) was significantly higher in diabetics than non-diabetics (348+/-198 vs 137+/-311 ml/day, P=0.02). Our results show that icodextrin produces significantly higher UF in long-day dwell in diabetic ESRD patients on CCPD than in non-diabetic patients. The reason for this difference is not clear.

Topics: Aged; Analysis of Variance; Diabetes Mellitus; Dialysis Solutions; Diuretics; Female; Furosemide; Glucans; Glucose; Hemofiltration; Humans; Icodextrin; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Retrospective Studies; Treatment Outcome

Topics: Blood Glucose; Blood Pressure Monitors; Diabetes Mellitus; Dialysis Solutions; Glucans; Glucose; Humans; Icodextrin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Renal Insufficiency

Maltose, a disaccharide composed of two glucose molecules, is used in a number of biological preparations as a stabilizing agent or osmolality regulator. Icodextrin, which is converted to maltose, is present in a peritoneal dialysis solution. Galactose and xylose are found in some foods, herbs, and dietary supplements; they are also used in diagnostic tests. When some blood glucose monitoring systems are used--specifically, those that use test strips containing the enzymes glucose dehydrogenase-pyrroloquinolinequinone or glucose dye oxidoreductase--in patients receiving maltose, icodextrin, galactose, or xylose, interference of blood glucose levels can occur. Maltose, icodextrin, galactose, and xylose are misinterpreted as glucose, which can result in erroneously elevated serum glucose levels. This interference can result in the administration of insulin, which may lead to hypoglycemia. In severe cases of hypoglycemia, deaths have occurred. If patients are receiving maltose, icodextrin, galactose, or xylose, clinicians must review the package inserts of all test strips to determine the type of glucose monitoring system being used and to use only those systems whose tests strips contain glucose oxidase, glucose dehydrogenase-nicotinamide adenine dinucleotide, or glucose dehydrogenase-flavin adenine dinucleotide.

Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus; Dialysis Solutions; Drug Labeling; Galactose; Glucans; Glucose; Humans; Icodextrin; Maltose; Reagent Strips; Reproducibility of Results; Xylose

Glucose absorbed from conventional peritoneal dialysis (PD) solutions contributes to unfavorable metabolic effects. Its replacement with a glucose-free osmotic agent such as icodextrin (ID) or amino acids (AA) may have some benefit on glucose and lipid metabolism.. Serum lipids, insulin sensitivity and substrate oxidation (calorimetry) were measured before and after 8 weeks use of ID or AA in 22 patients. Calorimetry and blood tests (HbA1c, lipids) were also performed after 8 weeks of simultaneous use of ID and AA in 8 patients.. Cholesterol declined during the use of AA (4.8 +/- 0.3-4.5 +/- 0.3 mmol/l, p = 0.045). Triglycerides decreased during the use of both ID (2.2 +/- 0.2-1.9 +/- 0.1 mmol/l, p = 0.019) and AA (1.9 +/- 0.2-1.6 +/- 0.1 mmol/l, p = 0.024). Free fatty acids declined during the use of AA. There were no significant changes in insulin sensitivity. Glucose oxidation decreased and lipid oxidation increased during the use of ID, the changes in substrate oxidation were accentuated during the simultaneous use of ID and AA.. Replacement of glucose with ID or AA had a benefit on glucose and lipid metabolism.

Topics: Adult; Aged; Amino Acids; Diabetes Mellitus; Female; Glucans; Glucose; Hemodialysis Solutions; Humans; Icodextrin; Lipid Metabolism; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory

From 20% to 40% of all patients commencing dialysis are diabetic. The quality of glycemic control is an important determinant of outcome. The aims of this study were to investigate the use of the continuous glucose monitoring system (CGMS) to assess overall 24-hour glycemic control and the effects of both nonglucose containing and more biocompatible alternative peritoneal dialysis solutions in insulin-treated continuous ambulatory peritoneal dialysis (CAPD) patients.. We studied 8 insulin treated diabetic CAPD patients. A CGMS probe was inserted [allowing automatic measurement of interstitial fluid (ISF) glucose every 5 minutes, for a 72-hour period]. The patients were then allowed home with CGMS monitoring to assess the effect on glycemic control of three differing peritoneal dialysis regimes. Phase 1 consisted of three exchanges of 1.36% glucose and one of 3.86% glucose, utilizing a lactate/bicarbonate buffer. Phase 2 was identical but used lactate-buffered fluid alone. Phase 3 utilized a minimally glycemic combination of one amino acid, one icodextrin, and two 1.36% glucose lactate/bicarbonate-containing exchanges.. ISF glucose measured by CGMS correlated well with venous glucose measurements (r2 = 0.82, P < 0.0001). There was a statistically significant difference in the mean ISF glucose between all three phases (P < 0.0001). The variation in glycemic control was tighter during phase 3 [mean coefficient of variation (CV) 0.21 +/- 0.03].. CGMS appears to be a clinically useful tool to gain additional insights into the glycemic control of diabetic CAPD patients. More biocompatible and nonglucose-containing dialysis fluids seem to be associated with improvements in glycemic control in this group of patients.

Topics: Adult; Aged; Bicarbonates; Blood Glucose; Buffers; Creatinine; Diabetes Mellitus; Dialysis Solutions; Glucans; Glucose; Humans; Hypoglycemic Agents; Icodextrin; Insulin; Lactic Acid; Middle Aged; Monitoring, Physiologic; Peritoneal Dialysis, Continuous Ambulatory; Peritoneum; Veins